BGC-0228 is under clinical development by BrightGene Bio-Medical Technology and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition ...
Some results have been hidden because they may be inaccessible to you